Show simple item record

dc.contributor.authorKasper, Christoph
dc.contributor.authorSchwarzer, A
dc.contributor.authorDe Wynter, Erika A
dc.contributor.authorChang, James
dc.contributor.authorDexter, T Michael
dc.contributor.authorRyder, W David J
dc.contributor.authorTesta, Nydia G
dc.date.accessioned2010-02-12T16:09:26Z
dc.date.available2010-02-12T16:09:26Z
dc.date.issued1998-06
dc.identifier.citationRecombinant human megakaryocyte growth and development factor (MGDF) increases the numbers of megakaryocyte progenitor cells to normal values in long-term bone marrow cultures of patients with AML in first remission. 1998, 12 (6):907-11 Leukemiaen
dc.identifier.issn0887-6924
dc.identifier.pmid9639419
dc.identifier.urihttp://hdl.handle.net/10541/92034
dc.description.abstractThe megakaryopoietic potential in the bone marrow (BM) of patients in first remission after treatment for acute myelogenous leukaemia (AML) was investigated using long-term bone marrow cultures (LTC) stimulated with megakaryocyte growth and development factor (MGDF). The baseline number of megakaryocyte colony-forming cells (Meg-CFC) was very low. However, there was a 10 to 100-fold increase of Meg-CFC in cultures treated with 10 ng/ml MGDF with mean numbers within the normal range for the first 4 weeks of culture with a 24-fold increase in their cumulative numbers. Similarly, a 12-fold increase in the numbers of megakaryocytes (MKs) was found by CD61 immunostaining. These effects were lost at the dose of 100 ng/ml. In contrast, the cumulative mean numbers of Meg-CFC in the control cultures from normal bone marrow (NBM) were not significantly different from those in cultures treated with 10 or 100 ng/ml MGDF. These results demonstrate that MGDF stimulates megakaryocytopoiesis in patients with AML in first remission, restoring the Meg-CFC compartment to normal values, a result with potential clinical implications for their treatment with autologous transplantation.
dc.language.isoenen
dc.subjectHaematopoiesisen
dc.subjectHaematopoietic Stem Cellsen
dc.subjectAcute Myeloid Leukaemiaen
dc.subjectCancer Proteinsen
dc.subject.meshAdult
dc.subject.meshBone Marrow Cells
dc.subject.meshCell Count
dc.subject.meshCulture Techniques
dc.subject.meshFemale
dc.subject.meshHematopoiesis
dc.subject.meshHematopoietic Stem Cells
dc.subject.meshHumans
dc.subject.meshLeukemia, Myeloid, Acute
dc.subject.meshMale
dc.subject.meshMegakaryocytes
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Proteins
dc.subject.meshProto-Oncogene Proteins
dc.subject.meshReceptors, Cytokine
dc.subject.meshReceptors, Thrombopoietin
dc.subject.meshRecombinant Proteins
dc.subject.meshReference Values
dc.titleRecombinant human megakaryocyte growth and development factor (MGDF) increases the numbers of megakaryocyte progenitor cells to normal values in long-term bone marrow cultures of patients with AML in first remission.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Experimental Haematology, Paterson Institute for Cancer Research, Manchester, UK.en
dc.identifier.journalLeukemiaen
html.description.abstractThe megakaryopoietic potential in the bone marrow (BM) of patients in first remission after treatment for acute myelogenous leukaemia (AML) was investigated using long-term bone marrow cultures (LTC) stimulated with megakaryocyte growth and development factor (MGDF). The baseline number of megakaryocyte colony-forming cells (Meg-CFC) was very low. However, there was a 10 to 100-fold increase of Meg-CFC in cultures treated with 10 ng/ml MGDF with mean numbers within the normal range for the first 4 weeks of culture with a 24-fold increase in their cumulative numbers. Similarly, a 12-fold increase in the numbers of megakaryocytes (MKs) was found by CD61 immunostaining. These effects were lost at the dose of 100 ng/ml. In contrast, the cumulative mean numbers of Meg-CFC in the control cultures from normal bone marrow (NBM) were not significantly different from those in cultures treated with 10 or 100 ng/ml MGDF. These results demonstrate that MGDF stimulates megakaryocytopoiesis in patients with AML in first remission, restoring the Meg-CFC compartment to normal values, a result with potential clinical implications for their treatment with autologous transplantation.


This item appears in the following Collection(s)

Show simple item record